Israel Starts Widespread Use of Regeneron's COVID Treatment in High-risk Patients

Ido Efrati
Ido Efrati
Send in e-mailSend in e-mail
Send in e-mailSend in e-mail
Ido Efrati
Ido Efrati

A coronavirus drug for patients in mild to moderate condition who are at high risk of deteriorating into serious condition will now be provided through Health Maintenance Organizations – and not just in hospitals and geriatric institutions, the Health Ministry has said.

HMOs will provide Regeneron Pharmaceuticals' REGEN-COV drug from Thursday, and each will set the criteria determining which patients are eligible to receive it. The Health Ministry has not yet set official protocol for using the drug, and the policy currently varies from hospital to hospital.

Click the alert icon to follow topics:

Comments